Vaccine. 2018 Jun 13. pii: S0264-410X(18)30772-2. doi: 10.1016/j.vaccine.2018.05.105. Available online 13 June 2018
Letter to the Editor
New pentavalent rotavirus vaccine shows little efficacy against diarrhea
Department of Pediatrics, St Stephens Hospital, Delhi 110054, India
Keywords: Rotarix; Bovine human-reassortant pentavalent vaccine; Serum Institute of India
Rotavirus vaccine is recommended as a means of reducing diarrheal morbidity and deaths in developing countries . The original efficacy studies with the presently licensed vaccines were done in the USA and Europe. Efficacy against severe rotavirus infection was around 90% (95% confidence interval (CI) : 85.Â·1â€’â€“94.Â·1) and against all-cause severe gastroenteritis it was about 50% (CI: 39.Â·8â€’â€“57.Â·8) . Efficacy was less in Africa and Asia. In Africa it was 61% (CI: 44.0â€’0â€“73.2) 2) against severe rotavirus diarrhoea and 30% (CI: 15.0â€’â€“42.6) against all-cause severe diarrhoea .
The journal Vaccine has now published the results of a Phase-III randomized-control-trial, of a newly developed pentavalent rotavirus vaccine (BRV-PV). Vaccine efficacy against rotavirus diarrhoea ,(39.5% efficacy against severe rotavirus gastroenteritis (SRVGE) in the per protocol analysis) is emphasized in the report. However, the incidence of â€˜all-cause severe gastroenteritisâ€™ was not reduced by vaccination â€“ vaccine efficacy was reported as 4.6% (95% CI: -âˆ’5.1â€’ to 13.4) .
From the standpoint of the scientific record, additionally highlighting the clinically relevant aspect of their findings - namely efficacy against all-cause diarrheal morbidity, would enable decision makers to make choices about the vaccine, considering costs and benefits.
The same vaccine was studied in Niger. An efficacy of 66.7% against severe rotavirus gastroenteritis was reported in the per protocol population . However severe gastroenteritis due to any etiology was not significantly lower among the vaccinated (difference in rate 1.97 cases per 100 person years confidence interval [CI](CI: â€“- 1.,28 to â€“5.22) . The authors did post-hoc analysis of efficacy against â€˜very severe diarrhoeaâ€™ (which they defined as Vesikari score of 15 or more) and reported a difference in rate of 3.08 per 100 person years (CI: 1.79 to â€“4.36) among the vaccinated. As efficacy against â€˜very severe diarrheaâ€™ has not been studied previously, comparable data for other rotavirus vaccines is not available.
 Rotavirus vaccines. WHO position paper -January 2013. Wkly Epidemiol Rec 2013;88(5):49â€“64.
 T. Vesikari, A. Karvonen, R. Prymula, V. Schuster, J.C. Tejedor, R. Cohen, et al., Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind T controlled study, Lancet 370, 2007, 1757â€“1763.
 S.A. Madhi, N.A. Cunliffe, D. Steele, D. Witte, M. Kirsten, C. Louw, et al., Effect of human rotavirus vaccine on severe diarrhea in African infants, N Engl J Med 362 (4), 2010 Jan 28, 289â€“298.
 P.S. Kulkarni, S. Desai, T. Tewari, A. Kawade, N. Goyal, B.S. Garg, et al., Flores J; SII BRV-PV author group. A randomized Phase III clinical trial to assess the efficacy of a bovine-human reassortantpentavalent rotavirus vaccine in Indian infants, Vaccine 35, 2017, 6228â€“6237.
 S. Isanaka, O. Guindo, C. Langendorf, A. Matar Seck, B.D. Plikaytis, N. Sayinzoga-Makombe, et al., Efficacy of a low-cost, heat-stable oral rotavirus vaccine in Niger, N Engl J Med 376, 2017, 1121â€“1130.
 J. Kaur and J. Puliyel, Heat-stable oral rotavirus vaccine, N Engl J M